KIT and melanoma: On the other hand, mutant c-KIT may be able to be targeted by tyrosine kinase receptor inhibitors (e.g., imatinib, sunitinib, and dasatinib), although, at present, clinical benefits have been reported only for imatinib in melanoma patients with KIT point mutations in exon 11 or 13, and not in those harboring gene amplification [8].